
Quotient Therapeutics kicks-off with US$50m financing
Flagship has confírmed to invest $50m in Quotient Therapeutics to advance development of a platform, licenced from Wellcome Sanger Institue...

SeaBeLife secures €1.2m in funding
SeaBeLife SAS has secured €1.2m in funding, aiming to develop unique drug candidates that block cell necrosis and target two regulated cell death...

Crucible Therapeutics spins out with £5m
Crucible Therapeutics Ltd., the newly launched spinout company from the University of Sheffield, secured the investment of £5m from Northern...

BioNtech reports Car-T/mRNA booster study results at ESMO
Testing different dose levels of its adoptive cell therapy BNT.221-01, a combination of Claudin 6 (CLDN6)-targeted Car-T cells (derived from...

Majority of EU agri-council supports NGT deregulation
On the occasion of an informal meeting of EU agriculture ministers on NGT plant varieties (3.–5. September), a majority of ministers said they would...

Repairing MS-caused damage with stem cells
Results of a investigator-initiated Phase I stem cell therapy trial have shown promise as a treatment for progressive multiple sclerosis. The...

Solar Foods raises €8m in Series B financing
Solar Foods Oy has raised €8m (US$8.8m) from retail investors in Finland. The Series B round was led by Finland’s Springvest Oy, existing...